CO6430423A2 - Combinaciones farmaceuticas que comprenden rdea119/bay 869766 para el tratamiento de canceres especificos - Google Patents
Combinaciones farmaceuticas que comprenden rdea119/bay 869766 para el tratamiento de canceres especificosInfo
- Publication number
- CO6430423A2 CO6430423A2 CO11116967A CO11116967A CO6430423A2 CO 6430423 A2 CO6430423 A2 CO 6430423A2 CO 11116967 A CO11116967 A CO 11116967A CO 11116967 A CO11116967 A CO 11116967A CO 6430423 A2 CO6430423 A2 CO 6430423A2
- Authority
- CO
- Colombia
- Prior art keywords
- cancer
- pharmaceutical combinations
- rdea119
- bay
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- RDSACQWTXKSHJT-NSHDSACASA-N n-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2s)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide Chemical compound C1CC1(C[C@H](O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-NSHDSACASA-N 0.000 title 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- -1 3,4-difluoro-2- (2-fluoro-4-iodophenylamino) -6 -methoxy-phenyl Chemical group 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 208000024770 Thyroid neoplasm Diseases 0.000 abstract 1
- 208000009956 adenocarcinoma Diseases 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 201000002510 thyroid cancer Diseases 0.000 abstract 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15940309P | 2009-03-11 | 2009-03-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6430423A2 true CO6430423A2 (es) | 2012-04-30 |
Family
ID=42135921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO11116967A CO6430423A2 (es) | 2009-03-11 | 2011-09-09 | Combinaciones farmaceuticas que comprenden rdea119/bay 869766 para el tratamiento de canceres especificos |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8673876B2 (enExample) |
| EP (1) | EP2405908B1 (enExample) |
| JP (2) | JP5767122B2 (enExample) |
| KR (1) | KR20110132371A (enExample) |
| CN (2) | CN103948600A (enExample) |
| AU (1) | AU2010224044A1 (enExample) |
| BR (1) | BRPI1009448A2 (enExample) |
| CA (2) | CA2754913C (enExample) |
| CL (1) | CL2011002233A1 (enExample) |
| CO (1) | CO6430423A2 (enExample) |
| CR (1) | CR20110479A (enExample) |
| CU (1) | CU20110170A7 (enExample) |
| DO (1) | DOP2011000282A (enExample) |
| EA (1) | EA201101302A1 (enExample) |
| EC (1) | ECSP11011314A (enExample) |
| HK (1) | HK1199710A1 (enExample) |
| IL (1) | IL214749A0 (enExample) |
| MA (1) | MA33091B1 (enExample) |
| MX (1) | MX2011009498A (enExample) |
| PE (1) | PE20120105A1 (enExample) |
| SG (1) | SG174272A1 (enExample) |
| TN (1) | TN2011000455A1 (enExample) |
| WO (1) | WO2010105110A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| AU2009296246B2 (en) | 2008-09-26 | 2015-07-30 | Oncomed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| WO2013001372A2 (en) * | 2011-06-30 | 2013-01-03 | University Of Oslo | Methods and compositions for inhibition of activation of regulatory t cells |
| WO2013086260A2 (en) * | 2011-12-09 | 2013-06-13 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of cancer |
| CA2890238A1 (en) | 2012-11-02 | 2014-05-08 | Merck Patent Gmbh | Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor |
| CN105073195A (zh) | 2013-02-04 | 2015-11-18 | 昂科梅德制药有限公司 | 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测 |
| US20160220494A1 (en) * | 2013-09-13 | 2016-08-04 | Bayer Pharma Aktiengesellschaft | Pharmaceutical compositions containing refametinib |
| EP2848246A1 (en) * | 2013-09-13 | 2015-03-18 | Bayer Pharma Aktiengesellschaft | Pharmaceutical compositions containing refametinib |
| US20170114323A1 (en) | 2014-06-19 | 2017-04-27 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
| US12371667B2 (en) | 2021-05-13 | 2025-07-29 | Washington University | Enhanced methods for inducing and maintaining naive human pluripotent stem cells |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9925958D0 (en) | 1999-11-02 | 1999-12-29 | Bundred Nigel J | Therapeutic use |
| AU2002234165A1 (en) * | 2000-11-03 | 2002-05-27 | Tularik, Inc. | Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents |
| AU2002340139A1 (en) * | 2001-10-09 | 2003-04-22 | The University Of Cincinnati | Inhibitors of the egf receptor for the treatment of thyroid cancer |
| MXPA05011296A (es) * | 2003-04-25 | 2006-01-24 | Gilead Sciences Inc | Conjugados de fosfonato inhibidores de la cinasa. |
| RU2007119432A (ru) | 2004-12-17 | 2009-01-27 | Смитклайн Бичам (Корк) Лимитед (Ie) | Способ лечения рака |
| US20060211074A1 (en) * | 2005-01-12 | 2006-09-21 | Boyce James P | Kinase-directed, activity-based probes |
| JP5106098B2 (ja) * | 2005-02-28 | 2012-12-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | スルホンアミド化合物の抗癌剤との新規併用 |
| US8101799B2 (en) | 2005-07-21 | 2012-01-24 | Ardea Biosciences | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
| ES2481402T3 (es) * | 2005-07-21 | 2014-07-30 | Ardea Biosciences, Inc. | Inhibidores de N-(arilamino)sulfonamida de MEK |
| US20090017050A1 (en) | 2007-07-13 | 2009-01-15 | Ventana Medical Systems, Inc. | Egfr antigen-binding molecules and uses thereof |
| AU2008282338B2 (en) * | 2007-07-30 | 2015-02-12 | Ardea Biosciences, Inc. | Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same |
| EP2175885B1 (en) * | 2007-07-30 | 2016-10-12 | Ardea Biosciences, Inc. | Combinations of mek inhibitors and raf kinase inhibitors and uses thereof |
| US8044240B2 (en) * | 2008-03-06 | 2011-10-25 | Ardea Biosciences Inc. | Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof |
| DE102008031039A1 (de) * | 2008-06-30 | 2009-12-31 | Dömling, Alexander, Priv.-Doz. Dr. | Tarceva zur Anwendung in der Organtransplantation. |
-
2010
- 2010-03-11 EA EA201101302A patent/EA201101302A1/ru unknown
- 2010-03-11 EP EP10709139.9A patent/EP2405908B1/en active Active
- 2010-03-11 CA CA2754913A patent/CA2754913C/en not_active Expired - Fee Related
- 2010-03-11 JP JP2011554220A patent/JP5767122B2/ja not_active Expired - Fee Related
- 2010-03-11 KR KR1020117021234A patent/KR20110132371A/ko not_active Withdrawn
- 2010-03-11 CA CA2972379A patent/CA2972379A1/en not_active Abandoned
- 2010-03-11 AU AU2010224044A patent/AU2010224044A1/en not_active Abandoned
- 2010-03-11 BR BRPI1009448A patent/BRPI1009448A2/pt not_active IP Right Cessation
- 2010-03-11 MA MA34134A patent/MA33091B1/fr unknown
- 2010-03-11 CN CN201310462579.9A patent/CN103948600A/zh active Pending
- 2010-03-11 WO PCT/US2010/027060 patent/WO2010105110A1/en not_active Ceased
- 2010-03-11 US US13/255,278 patent/US8673876B2/en not_active Expired - Fee Related
- 2010-03-11 CN CN2010800209977A patent/CN102421427B/zh not_active Expired - Fee Related
- 2010-03-11 MX MX2011009498A patent/MX2011009498A/es not_active Application Discontinuation
- 2010-03-11 SG SG2011064300A patent/SG174272A1/en unknown
- 2010-03-11 PE PE2011001622A patent/PE20120105A1/es not_active Application Discontinuation
-
2011
- 2011-08-18 IL IL214749A patent/IL214749A0/en unknown
- 2011-09-09 TN TN2011000455A patent/TN2011000455A1/fr unknown
- 2011-09-09 CR CR20110479A patent/CR20110479A/es unknown
- 2011-09-09 EC EC2011011314A patent/ECSP11011314A/es unknown
- 2011-09-09 CL CL2011002233A patent/CL2011002233A1/es unknown
- 2011-09-09 CO CO11116967A patent/CO6430423A2/es not_active Application Discontinuation
- 2011-09-09 DO DO2011000282A patent/DOP2011000282A/es unknown
- 2011-09-09 CU CU20110170A patent/CU20110170A7/es unknown
-
2013
- 2013-11-18 US US14/082,681 patent/US9220696B2/en not_active Expired - Fee Related
-
2014
- 2014-09-04 JP JP2014180216A patent/JP5911929B2/ja not_active Expired - Fee Related
-
2015
- 2015-01-08 HK HK15100195.6A patent/HK1199710A1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6430423A2 (es) | Combinaciones farmaceuticas que comprenden rdea119/bay 869766 para el tratamiento de canceres especificos | |
| MX2018005071A (es) | Tratamiento del cancer de pulmon de celulas pequeñas con un inhibidor de parp. | |
| MX2013002084A (es) | Biomarcadores y metodos de tratamiento. | |
| MX351889B (es) | Composiciones y métodos anti-cxcr1. | |
| MX2019013723A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
| MX2019000225A (es) | Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades. | |
| PH12012501782A1 (en) | Phytocannabinoids in the treatment of cancer | |
| NZ701575A (en) | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer | |
| PH12014501560A1 (en) | Carbamate compounds and of making and using same | |
| AR060306A1 (es) | Terapia de combinacion de anticuerpos contra ctla4 | |
| MD20160016A2 (ro) | Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin | |
| NZ712479A (en) | Methods, compounds, and compositions for the treatment of angiotensin-related diseases | |
| WO2011121453A3 (en) | Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate | |
| NZ603952A (en) | Phosphaplatins and their use for treatment of cancers | |
| IN2014DN11205A (enExample) | ||
| EA201200046A1 (ru) | Новые соединения, фармацевтическая композиция и связанные с ними способы | |
| MX349550B (es) | 1,7-diazacarbazoles y metodos de uso. | |
| MX2017014641A (es) | Composiciones y metodos para inhibir la expresion del gen de factor inducible por hipoxia alfa (hif2alfa). | |
| MX2016016388A (es) | Uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de pulmon de celula no pequeña y/o cancer de pulmon de celula pequeña. | |
| BR112013026680A2 (pt) | composto, método de tratamento de uma doença inflamatória e composição farmacêutica | |
| NZ705124A (en) | Interferon-beta for use as monotherapy or in combination with other cancer therapies | |
| BR112015005443A2 (pt) | tratamento combinado com fármaco interferente de netrina-1 e fármaco quimioterápico | |
| FR2945210B1 (fr) | Combinaison antitumorale comprenant l'ave8062 et le sorafenib | |
| MX2019005104A (es) | Composiciones de zinc-y-pga y métodos para tratar el cancer. | |
| CY1120395T1 (el) | Παραγωγα στερολης και χρηση αυτων για την αγωγη νοσηματων που περιλαμβανουν μετασχηματισμενα αστροκυτταρα ή για την αγωγη κακοηθων αιμοπαθειων |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |